Abstract:Inspired by the success of dual-targeting drugs, especially bispecific antibodies, we propose to combine the concept of proteolysis targeting chimera (PROTAC) and dual targeting to design and synthesize dual PROTAC molecules with the function of degrading two completely different types of targets simultaneously. A library of novel dual-targeting PROTAC molecules has been rationally designed and prepared. A convergent synthetic strategy has been utilized to achieve high synthetic efficiency. These dual PROTAC structures are characterized using trifunctional natural amino acids as star-type core linkers to connect two independent inhibitors and E3 ligands together. In this study, gefitinib, olaparib, and CRBN or VHL E3 ligands were used as substrates to synthesize novel dual PROTACs. They successfully degraded both the epidermal growth factor receptor (EGFR) and poly(ADP-ribose) polymerase (PARP) simultaneously in cancer cells. Being the first successful example of dual PROTACs, this technique will greatly widen the range of application of the PROTAC method and open up a new field for drug discovery.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00649?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00649</a>.1H NMR spectra of compounds in the text, HRMS spectra of MP-GC, MP-OC, MP-GV, MP-OV, DP-C 1-4 and DP-V 1-4 and HPLC for purity determination of DP-C 1-4, DP-V 1-4, MP-GC, MP-OC, MP-GV, and MP-OV (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00649/suppl_file/jm1c00649_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00649/suppl_file/jm1c00649_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the Ataxia telangiectasia and RAD3-related (ATR) kinase

Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the ataxia telangiectasia and RAD3-related (ATR) kinase

Design, Synthesis, and Biological Evaluation of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase for the Efficient Treatment of Cancer

Design, synthesis, and biological evaluation of pyrido[3,2-d]pyrimidine derivatives as novel ATR inhibitors

Discovery of Thieno[3,2-d]pyrimidine Derivatives As Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase.

Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: Structural activity relationship and antitumor activity both in vitro and in vivo

Pharmacological degradation of ATR induces antiproliferative DNA replication stress in leukemic cells

Targeting ATR in patients with cancer

Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders

Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment

Distinct Amino Acid-Based PROTACs Target Oncogenic Kinases for Degradation in Non-Small Cell Lung Cancer (NSCLC)

Development Of Alectinib-Based Protacs As Novel Potent Degraders Of Anaplastic Lymphoma Kinase (Alk)

Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (protacs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells.

Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP

Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)

Discovery of selective and potent ATR degrader for exploration its kinase‐independent functions in acute myeloid leukemia cells

Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related Protein Kinase (ATR)

Discovery of 4-{4-[(3r)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1h-indole (AZ20): a Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity.

Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor Undergoing Phase 2 Clinical Studies for the Treatment of Advanced or Metastatic Solid Cancers

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future

Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment